Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

    Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

    Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

    We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

    1. Home

    2. Perspectives

    3. The next generation of scientists

    The next generation of scientists

    Meet Johanna Wagner: She is part of the  Department of Quantitative Biomedicine and focuses on cancer research using single-cell technologies.

    2min
    Santina Russo
    Published on January 14, 2020

    In today’s world, scientists of different fields need to work together – for better research, to improve patient care, and for their own success. PhD programs, which provide an interdisciplinary network, can facilitate collaborations. Students in Zurich tell us what they think the future holds for them.

    Breast cancer research using single-cell technologies

    The Molecular Life Sciences program is a joint initiative of two leading academic research centers in Switzerland, the ETH Zurich and the University of Zurich. Johanna Wagner is part of the relatively new Department of Quantitative Biomedicine and focuses on cancer research using single-cell technologies.

    “We analyzed millions of cells from 144 breast cancers with mass cytometry,” says Wagner. “This method enabled us to quantify dozens of proteins at the single-cell level. We see that each breast cancer is unique, which might explain why some patients respond to treatment and others not. Therefore, to improve patient care, precision medicine approaches are needed that consider and ideally exploit this uniqueness. We show that the detailed analysis of all cells in a cancer can enable a more precise patient classification – impacting both prognosis and treatment options.”

    The goal of Wagner’s work is “to empower precision medicine approaches by providing an atlas or a roadmap of cancer uniqueness. Because only when we know what is present in a cancer we can choose treatments that target exactly that.”

    The Patients’ Tumor Bank of Hope’s collaboration with the Department of Quantitative Biomedicine makes it possible for Johanna Wagner to research breast cancer.

    Wagner explains that the research is only possible because patients and hospitals collaborate with them, such as the Patients’ Tumor Bank of Hope, an initiative by breast cancer survivors who wanted their diseased tissue to be available for research. “Our work would not have been possible without this collaboration,” Wagner says.

    “Another step is to bridge basic biological research with data analysis. The data we generate is complex and not straightforward to analyze. We teamed up with external machine learning experts for the complex data analysis,” Wagner states. Still in the research phase, Wagner realizes the future of her work will require further collaboration: “Due to the costs associated with clinical trials, we need an industry partner to launch such an endeavor.”

    By Santina Russo
    Santina Russo is a freelance science and medical journalist based in Zurich, Switzerland.
    1. The statements by Siemens Healthineers customers described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.